PPAR
PPAR(过氧化物酶体增殖剂激活受体)
The peroxisome proliferator-activated receptors (PPARs), belonging to the nuclear receptor superfamily, are a group of nuclear receptor proteins that are composed of three isoforms, including PPARγ, PPARα and PPARδ, encoded by separate genes. PPARs have a modular structure characterized by the presence of two highly conserved domains, including the DNA binding domain (DBD) of two zinc fingers and the ligand binding domain (LBD) of 13 α-helices and a small 4-stranded β-sheet. PPARs are ligand-regulated transcription factors controlling gene expression by binding to specific response elements (PPREs) within promoters, where PPARs bind as heterodimers with a retinoid X receptor and interact with cofactors upon binding leading to the increasing of rate of transcription initiation.
PPAR 相关产品(215)
- GC13204InolitazoneCAS: 223132-37-4
Inolitazone 是一种新型的高亲和力 PPARγ 激动剂,其生物活性依赖于 PPARγ,抑制生长的 IC50 为 0.8 nM。
- GC14403WY-14643 (Pirinixic Acid)CAS: 50892-23-4纯度: >99.50% / >98.00%
WY-14643 (Pirinixic Acid)是一种高效、具备选择性高亲和力的过氧化物酶体增殖物激活受体α(PPARα)受体激动剂,对小鼠的 PPARα受体的EC 50 为0.63μM,对人的 PPARα受体的EC 50 为5μM。
- GC15272TroglitazoneCAS: 97322-87-7纯度: >98.50% / >98.00% / >96.00%
Troglitazone是一种具有口服活性的过氧化物酶体增殖物激活受体γ(PPARγ)激动剂,对人和鼠的EC 50 值分别为550nM和780nM。
- GC16444RosiglitazoneCAS: 122320-73-4纯度: >99.50% / >98.00%
Rosiglitazone是一种具有口服活性的过氧化物酶体增殖物活化受体γ(PPARγ )选择性激动剂,选择性地激活含有PPARγ配体结合域(LBD)的嵌合体,而不是PPARα和PPARδ,EC 50 为60 nM,K d 为40 nM。
- GC10190DG-172 (hydrochloride)CAS: 1361504-77-9纯度: >99.00%
An orally available PPARβ/δ inverse agonist
| 货号 | 产品名称 | CAS号 | 纯度 | 结构 |
|---|---|---|---|---|
| GC11152 | Pioglitazone HCl | 112529-15-4 | >99.50% | |
A PPARγ agonist | ||||
| GC11318 | Rosiglitazone maleate | 155141-29-0 | >99.50% | |
A PPARγ agonist | ||||
| GC11423 | GW1929 | 196808-24-9 | >99.50% | |
A non-thiazolidinedione activator of PPARγ | ||||
| GC12820 | T0070907 | 313516-66-4 | >99.50% | |
T0070907是一种有效的选择性过氧化物酶体增殖物激活受体γ(PPARγ)拮抗剂,IC 50 值为1nM。 | ||||
| GC12894 | Balaglitazone | 199113-98-9 | >99.50% | |
A partial agonist of PPARγ | ||||
| GC13204 | Inolitazone | 223132-37-4 | - | |
Inolitazone 是一种新型的高亲和力 PPARγ 激动剂,其生物活性依赖于 PPARγ,抑制生长的 IC50 为 0.8 nM。 | ||||
| GC13633 | Ciprofibrate | 52214-84-3 | >99.50% | |
A selective PPARα agonist | ||||
| GC13969 | GW9662 | 22978-25-2 | >99.50% / >98.00% | |
GW9662是一种特异性的过氧化物酶体增殖物激活受体-γ(PPAR-γ)抑制剂,其IC50为3.3 nM。 | ||||
| GC14403 | WY-14643 (Pirinixic Acid) | 50892-23-4 | >99.50% / >98.00% | |
WY-14643 (Pirinixic Acid)是一种高效、具备选择性高亲和力的过氧化物酶体增殖物激活受体α(PPARα)受体激动剂,对小鼠的 PPARα受体的EC 50 为0.63μM,对人的 PPARα受体的EC 50 为5μM。 | ||||
| GC14983 | GW0742 | 317318-84-6 | >98.00% | |
A selective agonist of PPARδ | ||||
| GC15272 | Troglitazone | 97322-87-7 | >98.50% / >98.00% / >96.00% | |
Troglitazone是一种具有口服活性的过氧化物酶体增殖物激活受体γ(PPARγ)激动剂,对人和鼠的EC 50 值分别为550nM和780nM。 | ||||
| GC15318 | GW501516 | 317318-70-0 | >99.00% | |
GW501516是一种合成PPARδ特异性激动剂,EC 50 值为0.10nM。 | ||||
| GC15516 | Rosiglitazone HCl | 302543-62-0 | - | |
A PPARγ agonist | ||||
| GC16009 | GSK3787 | 188591-46-0 | >99.00% | |
A selective, irreversible PPARβ/δ antagonist | ||||
| GC16444 | Rosiglitazone | 122320-73-4 | >99.50% / >98.00% | |
Rosiglitazone是一种具有口服活性的过氧化物酶体增殖物活化受体γ(PPARγ )选择性激动剂,选择性地激活含有PPARγ配体结合域(LBD)的嵌合体,而不是PPARα和PPARδ,EC 50 为60 nM,K d 为40 nM。 | ||||
| GC18151 | Elafibranor (GFT505) | 923978-27-2 | >99.00% | |
An agonist of PPARα and PPARδ | ||||
| GC10190 | DG-172 (hydrochloride) | 1361504-77-9 | >99.00% | |
An orally available PPARβ/δ inverse agonist | ||||
| GC10381 | AUDA | 479413-70-2 | >98.00% | |
A potent inhibitor of soluble epoxide hydrolase | ||||
| GC11170 | Choline Fenofibrate | 856676-23-8 | >98.00% | |
非诺贝特胆碱 (ABT-335) 是一种非诺贝酸的胆碱盐,可在胃肠道中释放游离的非诺贝酸。 | ||||
| GC11477 | Darglitazone | 141200-24-0 | >99.00% | |
A PPARγ agonist | ||||
| GC11586 | SR 202 | 76541-72-5 | >99.50% | |
An antagonist of agonist-induced PPARγ transcriptional activity | ||||
| GC11732 | GW 590735 | 622402-22-6;343321-96-0 | - | |
A potent and selective agonist of PPARα | ||||
| GC11916 | GQ-16 | 870554-67-9 | - | |
A PPARγ partial agonist | ||||
| GC12062 | nTZDpa | 118414-59-8 | - | |
PPARγ partial agonist | ||||
